Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Xa activity of reduced-dose nadroparin in renal impairment
NL-OMON23816Unknown
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- Jan 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of nadroparin in venous thromboembolism (VTE) and arterial thromboembolism (2 arms), sponsored by Medisch Centrum Leeuwarden. Primary endpoint: Mean anti-Xa activity by renal function group. Status: unknown.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)arterial thromboembolism
Beyond the preview
Go deeper on NL-OMON23816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23816.